For how we live.
GUARDIAN offered parents of 4,000 babies a genomic screen for 156 treatable conditions on top of the standard heel-prick. Most said yes, and sequencing worked in 99.6% of cases.
Men who carry a BRCA2 mutation develop prostate cancer earlier and in more aggressive forms. Trial evidence now supports offering them PSA screening from 40; the case for BRCA1 carriers is weaker.
23andMe's cleared BRCA report reads 3 of more than 1,000 mutations, so a negative result is not the all-clear it looks like — and the firm's bankruptcy has put customers' genetic data in play.
A scoping review mapped 204 consumer nutrigenetic panels at a mean price of $234. Across them, 3,309 different genes were linked to dietary recommendations.
WISDOM randomised 28,372 women to annual mammography or a risk-tailored schedule. The risk-based arm met its non-inferiority mark for advanced cancers — with caveats about who enrolled.